Tilak Kumar Sundaresan MD

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

55 Fruit StYawkey 7bBoston, MA 02114
Phone+1 617-632-3779

Dr. Sundaresan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sundaresan's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2008 - 2011
Rutgers Robert Wood Johnson Medical SchoolClass of 2008

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2010 - 2028
MA State Medical License 2011 - 2018
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Vivek Subbiah, Fengmin Zhao, Ragini R Kudchadkar, Ryan J Sullivan, Helen X Chen
Clinical Cancer Research. 2026-08-11
Author Correction: HER2 expression identifies dynamic functional states within circulating breast cancer cells.
Nicole Vincent Jordan, Aditya Bardia, Ben S Wittner, Cyril Benes, Matteo Ligorio
Nature. 2026-04-01
1 citations
Early identification of weight loss trajectories in advanced cancer and associations with survival.
Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus D Goncalves, Richard F Dunne
Journal of the National Cancer Institute. 2025-08-01